Insider Transactions in Q4 2024 at Day One Biopharmaceuticals, Inc. (DAWN)
Insider Transaction List (Q4 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 10
2024
|
Samuel C. Blackman HEAD OF R&D |
SELL
Open market or private sale
|
Direct |
30,000
-2.82%
|
$390,000
$13.31 P/Share
|
|
Nov 18
2024
|
Jeremy Bender CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
10,554
-8.87%
|
$137,202
$13.21 P/Share
|
|
Nov 18
2024
|
Charles N York Ii COO, CFO AND SECRETARY |
SELL
Open market or private sale
|
Direct |
2,602
-1.07%
|
$33,826
$13.21 P/Share
|
|
Nov 18
2024
|
Adam Dubow GENERAL COUNSEL |
SELL
Open market or private sale
|
Direct |
3,165
-8.96%
|
$41,145
$13.21 P/Share
|
|
Nov 18
2024
|
Samuel C. Blackman HEAD OF R&D |
SELL
Open market or private sale
|
Direct |
2,206
-0.21%
|
$28,678
$13.21 P/Share
|
|
Nov 15
2024
|
Jeremy Bender CHIEF EXECUTIVE OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
19,999
+5.52%
|
-
|
|
Nov 15
2024
|
Charles N York Ii COO, CFO AND SECRETARY |
BUY
Exercise of conversion of derivative security
|
Direct |
10,250
+1.4%
|
-
|
|
Nov 15
2024
|
Adam Dubow GENERAL COUNSEL |
BUY
Exercise of conversion of derivative security
|
Direct |
8,399
+7.9%
|
-
|
|
Nov 15
2024
|
Samuel C. Blackman HEAD OF R&D |
BUY
Exercise of conversion of derivative security
|
Direct |
8,686
+0.27%
|
-
|
|
Nov 11
2024
|
Samuel C. Blackman HEAD OF R&D |
SELL
Open market or private sale
|
Direct |
10,000
-0.94%
|
$160,000
$16.1 P/Share
|
|
Nov 08
2024
|
Samuel C. Blackman HEAD OF R&D |
SELL
Open market or private sale
|
Direct |
18,255
-1.68%
|
$292,080
$16.17 P/Share
|
|
Nov 07
2024
|
Samuel C. Blackman HEAD OF R&D |
SELL
Open market or private sale
|
Direct |
11,245
-1.03%
|
$179,920
$16.03 P/Share
|
|
Oct 31
2024
|
Samuel C. Blackman HEAD OF R&D |
SELL
Open market or private sale
|
Direct |
500
-0.05%
|
$8,000
$16.02 P/Share
|